Stock V5D1 DELTA 9 CANNABIS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Delta 9 Cannabis Inc. Deutsche Boerse AG

Equities

V5D1

CA2477541049

Pharmaceuticals

Market Closed - Deutsche Boerse AG
Other stock markets
 05:05:10 2024-04-26 am EDT 		5-day change 1st Jan Change
0.0182 EUR +65.45% Intraday chart for Delta 9 Cannabis Inc. -4.21% +44.44%
Apr. 01 Delta 9 Cannabis to Seek Cannabis Stores Acquisition CI
Apr. 01 Transcript : Delta 9 Cannabis Inc., 2023 Earnings Call, Apr 01, 2024

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 61.57 52.04 30.6 8.95 5.304 7.232 -
Enterprise Value (EV) 1 61.57 52.04 30.6 8.95 5.304 7.232 7.232
P/E ratio - -7.29 x - - - - -
Yield - - - - - - -
Capitalization / Revenue 1.94 x 1 x 0.49 x 0.14 x 0.07 x 0.1 x 0.08 x
EV / Revenue 1.94 x 1 x 0.49 x 0.14 x 0.07 x 0.1 x 0.08 x
EV / EBITDA -17.2 x 13.7 x 15.2 x -1.71 x 1.57 x -4.02 x 2.26 x
EV / FCF -2,353,400 x -12,015,994 x - - - - -
FCF Yield -0% -0% - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 87,963 102,039 105,515 149,166 212,167 289,273 -
Reference price 2 0.7000 0.5100 0.2900 0.0600 0.0250 0.0250 0.0250
Announcement Date 3/19/20 3/31/21 3/31/22 4/1/23 4/1/24 - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 31.77 52.05 62.29 63.23 71.07 75.8 86.6
EBITDA 1 -3.584 3.8 2.011 -5.248 3.377 -1.8 3.2
EBIT -2.2 -2.768 -7.639 - - - -
Operating Margin -6.92% -5.32% -12.26% - - - -
Earnings before Tax (EBT) - - - - - - -
Net income - -6.418 - - - - -
Net margin - -12.33% - - - - -
EPS - -0.0700 - - - - -
Free Cash Flow -26.16 -4.331 - - - - -
FCF margin -82.36% -8.32% - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 3/19/20 3/31/21 3/31/22 4/1/23 4/1/24 - -
1CAD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3
Net sales 1 12.48 17.5 15.69 17.56 16.9 18.25 18.44
EBITDA 1 - -0.391 -1.683 -1.48 -0.4756 1.362 1.031
EBIT - - - - - - -
Operating Margin - - - - - - -
Earnings before Tax (EBT) - - - - - - -
Net income - - - - - - -
Net margin - - - - - - -
EPS - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 5/16/22 8/15/22 11/15/22 4/1/23 5/15/23 8/14/23 11/14/23
1CAD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow -26.2 -4.33 - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 14 5.84 - - - - -
Capex / Sales 44.18% 11.22% - - - - -
Announcement Date 3/19/20 3/31/21 3/31/22 4/1/23 4/1/24 - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.025 CAD
Average target price
0.06 CAD
Spread / Average Target
+140.00%
Consensus

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. DN Stock
  4. V5D1 Stock
  5. Financials Delta 9 Cannabis Inc.